39.95
39.95 (0.59%)
As of Jul 10, 2023
Iveric Bio, Inc. [ISEE]
Source:
Company Overview
Iveric Bio, Inc is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. We are committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases, including earlier stages of age-related macular degeneration, or AMD.
| Country | United States |
| Headquarters | parsippany, new jersey |
| Phone Number | (609) 474-6755 |
| Industry | manufacturing |
| CEO | /S/ Glenn P. Sblendorio |
| Website | www.ivericbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-73.8 |
| Net Income | $-72.2 |
| Net Cash | $-8.7 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -11.3% |
| Profit as % of Stockholder Equity | -15.1% |
Management Effectiveness
| Return on Equity | 0% |
| Return on Assets | 0% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $613.4 |
| Total Liabilities | $136.4 |
| Operating Cash Flow | $-50.6 |
| Investing Cash Flow | $39.3 |
| Financing Cash Flow | $2.6 |
